Applicant : Roberto BURIONI

U.S. Serial No. : 10/502,307 Filed : July 22, 2004

Page : 4

## Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## 1-29. (Canceled)

- 30. (New) A composition for treating HCV infection or preventing viral transmission in a subject comprising administering an effective amount of an isolated antibody or its functional fragment, wherein the antibody comprises amino acid sequences SEQ ID NOs.7 and 8.
- 31. (New) The composition of claim 30, wherein said antibody or its fragment comprises human monoclonal antibody Fab fragment el37 or a full-size human monoclonal antibody comprising said Fab fragment.
- 32. (New) A composition for treating HCV infection or preventing viral transmission in a subject comprising administering an effective amount of isolated antibody or its functional fragment, wherein the antibody comprises amino acid sequences SEQ ID NOs.9 and 10.
- 33. (New) The composition of claim 32, wherein said antibody or its fragment comprises human monoclonal antibody Fab fragment e301 or a full-size human monoclonal antibody comprising said Fab fragment.
- 34. (New) The composition of claim 30 wherein the human antibody is a full-size IgGl molecule.
- 35. (New) The composition of claim 31 wherein the human antibody is a, full-size IgGl molecule.

Applicant : Roberto BURIONI

U.S. Serial No. : 10/502,307 Filed : July 22, 2004

Page : 5

36. (New) The composition of claim 32 wherein the human antibody is a full-size IgG1 molecule.

- 37. (New) The composition of claim 33 wherein the human antibody is a full-size IgGl molecule.
- 38. (New) Composition for anti-HCV therapy comprising in a therapeutically effective amount at least a human antibody, or its functional fragments, said antibody or its fragment being the human monoclonal antibody Fab fragments e301 or e137, or a full-size human monoclonal antibody containing any of said Fab fragments.
- 39. (New) The composition according to claim 38 for parenteral or topical use in gel, creme, ointment and ovule formulations.